BCAL Diagnostics Limited (ASX:BDX – Get Free Report) insider Jayne Shaw purchased 125,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was bought at an average cost of A$0.12 ($0.08) per share, for a total transaction of A$14,375.00 ($9,712.84).
BCAL Diagnostics Price Performance
The company has a debt-to-equity ratio of 17.74, a current ratio of 3.60 and a quick ratio of 6.70.
BCAL Diagnostics Company Profile
See Also
- Five stocks we like better than BCAL Diagnostics
- Conference Calls and Individual Investors
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Pros And Cons Of Monthly Dividend Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is a Stock Market Index and How Do You Use Them?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.